WO2006029189A2 - Topical medicament - Google Patents

Topical medicament

Info

Publication number
WO2006029189A2
WO2006029189A2 PCT/US2005/031819 US2005031819W WO2006029189A2 WO 2006029189 A2 WO2006029189 A2 WO 2006029189A2 US 2005031819 W US2005031819 W US 2005031819W WO 2006029189 A2 WO2006029189 A2 WO 2006029189A2
Authority
WO
Grant status
Application
Patent type
Prior art keywords
medicament
weight
preferably
activity
metabolic
Prior art date
Application number
PCT/US2005/031819
Other languages
French (fr)
Other versions
WO2006029189A3 (en )
Inventor
Clyde Morgan
Original Assignee
Clyde Morgan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125Camphor; Nuclear substituted derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/748Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738Rosa (rose)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/752Citrus, e.g. lime, orange or lemon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/886Aloeaceae (Aloe family), e.g. aloe vera
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts

Abstract

New topical medicaments are provided. The medicaments comprise menthol and camphor, preferably provided as part of a base gel, supplemented with potassium and a source of oxygen. The most preferred base gel is sold under the name SOMBRA, while the most preferred source of oxygen is a chlorite (e.g., sodium chlorite) and/or spirulina. The medicaments provide high metabolic activities and sustain those activities over prolonged periods of time, thus being useful for treating a large variety of aliments, including diabetic neuropathy, post hepatic neuralgia, sclerodema, psoriasis, strain, spasticity, headaches, neuropathy secondary to drugs, peripheral neuropathy, leg pain, muscle cramps, muscle aches and pains, bruise, sinusitis, sprain, arthritis, joint pain (arthralgia), and edema.

Description

TOPICAL MEDICAMENT

BACKGROUND OF THE INVENTION Related Applications This application claims the priority benefit of U.S. Provisional Patent Application

No. 60/608,136, filed September 8, 2004, incorporated by reference herein.

Field of the Invention

The present invention is broadly concerned with improved topical medicaments in forms of creams or lotions which are useful in the treatment of a variety of conditions that are ameliorated by increased cell metabolism, circulation, and nerve function. More particularly, the invention is concerned with such medicaments having a gel base with menthol and camphor, and supplemented with potassium and an oxygen source such as an alkali metal chlorite.

Description of the Prior Art

A variety of topically applied creams and lotions have been developed in the past for treatment of conditions such as arthritis and muscle pains. One such product is commercialized under the designation SOMBRA. This product contains 3% menthol and 3% camphor, in a gel base, and is used for the temporary relief of minor aches and pains of muscles and joints associated with simple backaches, arthritis, strains, bruises, and sprains.

However, many prior art creams and lotions do not adequately treat these conditions in most people. Furthermore, even those that are successful do not sustain metabolic activity for extended periods of time, thus making any relief experienced rather temporary. There is a need for new treatments that provide relief for a wide variety of conditions and for extended periods of time.

SUMMARY OF THE INVENTION

The present invention overcomes these problems by broadly providing novel topical medicaments having improved metabolic activity. In more detail, the inventive medicaments comprise menthol, camphor, potassium, and a source of oxygen. The menthol and camphor can be individually added to the composition, or they can be added via a base composition including menthol and camphor. One preferred base composition is a gel sold under the name SOMBRA. Regardless of the delivery source, the menthol is preferably present in the medicament at a level of at least about 0.5% by weight, more preferably from about 2-20% by weight, and even more preferably from about 2-4% by weight, based upon the total weight of the medicament taken as 100% by weight. Furthermore, the camphor is preferably present in the medicament at a level of at least about 0.5% by weight, more preferably from about 2-20% by weight, and even more preferably from about 2-4% by weight, based upon the total weight of the medicament taken as 100% by weight.

The potassium is preferably provided in powder form, and it can be obtained from dietary supplements, for example. One preferred source of potassium is Potassium Chelate (99 mg potency) sold by Nature's Way. Potassium Chelate is provided in the form of a capsule including powder potassium and minor amounts of ground millet. The capsule can simply be opened, and the powder from the capsule used in the present invention. Potassium is preferably present in the medicament at a level of at least about 0.02% by weight, more preferably from about 0.04-0.5% by weight, and even more preferably from about 0.09-0.2% by weight, based upon the total weight of the medicament taken as 100% by weight. When Potassium Chelate or a similar product is used, preferably from about 1-20 capsules, more preferably from about 1-15 capsules, and even more preferably from about 8-13 capsules are used.

The source of oxygen can be any source that is capable of delivering the appropriate levels of oxygen to the medicament. Suitable oxygen sources include those selected from the group consisting of chlorites (and preferably alkali metal chlorites such sodium chlorite and magnesium chlorite), spirulina, and mixtures of the foregoing. The most preferred oxygen source is sold under the name AEROBIC 07, which contains deionized water, sodium chlorite, carbonates, and bicarbonates.

The oxygen source is preferably present in the medicament in sufficient quantities to provide oxygen levels of at least about 0.016% by weight, more preferably from about 0.10-0.85% by weight, and even more preferably from about 0.17-0.25% by weight, based upon the total weight of the medicament taken as 100% by weight. When AEROBIC 07 or a similar product is used, it is preferably added at levels of from about 1-13 drops, more preferably from about 1-10 drops, and even more preferably about 4 drops.

In one alternative embodiment, the medicament also includes a source of chlorine ions. If sodium chlorite is used as the source of oxygen, it will also functions as a source of chlorine ions. Other suitable sources of chlorine ions include any chlorite (e.g., sodium hypochlorite) such as those found in commercially available bleaching agents (e.g., CLOROX, CALIBEX). In these embodiments, the source of chlorine is included in sufficient quantities to provide chlorine ion levels of from about 0.10-10% by weight, and more preferably from about 0.16-0.85% by weight, based upon the total weight of the medicament taken as 100% by weight.

The inventive medicaments can also include a number of optional ingredients, depending upon the final use. Some suitable ingredients include those selected from the group consisting of aloe vera extract, capsaicin, carbomer, decyl plyglucose, deionized water, grapefruit seed extract, green tea extract, orange peel extract, queen of the prairie extract, rose water, silica, sodium hydroxymethyl glycinate, vegetable glycerin, witch hazel, yucca extract, carbonates, bicarbonates, and mixtures of the foregoing. The preferred quantities of these ingredients are set forth in Table 1. These ingredients can be added individually or in a group as part of another composition (e.g., in abase composition such as SOMBRA).

Table 1

A The percentages by weight are based upon the total weight of the topical medicament taken as 100% by weight.

The inventive medicaments are formed by simply mixing the above ingredients together, preferably in some type of carrier. If SOMBRA is used, then the carrier is provided by that product.

In a particularly preferred preparation method, a precursor composition containing the camphor and menthol is provided. The precursor composition should comprise: from about 1-10% by weight menthol, preferably from about 1-5% menthol, and even more preferably about 3% by weight menthol; and from about 1-10% by weight camphor, preferably from about 1-5% camphor, and even more preferably about 3% by weight camphor, based upon the total weight of the medicament taken as 100% by weight.

The precursor composition can also include some or all of the optional ingredients discussed above. A quantity of the precursor composition is added to a container, along with a portion of the potassium. Further respective quantities of the precursor composition and potassium are then added in alternating steps until the desired quantity as been obtained. The precursor composition and potassium within the container are preferably then mixed until substantially homogeneous (e.g., from about 1-3 minutes, and preferably about 2 minutes). Mixing can be carried out by hand or mechanical mixing means (e.g., mixer, shearing in industrial equipment). The source of oxygen is then added to the resulting mixture and further mixing is carried out. Any optional ingredients that were not already added can then be added to the mixture to yield the final medicament.

The inventive topical medicament is used to treat a portion of the body (human or animal) afflicted with an ailment by simply contacting the medicament with the afflicted portion of the body. The medicament is then preferably rubbed into the skin until it is no longer visible. It will be appreciated that the medicament can be used to treat numerous conditions, including diabetic neuropathy, post hepatic neuralgia, scleroderma, psoriasis, strain, spasticity, headaches, neuropathy secondary to drugs, peripheral neuropathy, leg pain, muscle cramps, muscle aches and pains, bruise, sinusitis, sprain, arthritis, joint pain

(arthralgia), and edema. •

The inventive medicament offers a particularly significant advantage in that it achieves high metabolic activity and maintains that activity over extended periods of time.

"Metabolic activity" as used herein refers to energy (in mV) that is created by the potassium ions in the medicament. That energy is then transferred to the patient at the medicament location on the skin. Though not wishing to be bound by theory, it is believed that the energy excites and thus opens the sodium-potassium pumps in the cells. This stimulates the nervous system and better allows active ingredients to enter the cells.

Metabolic activity is determined by mixing 1 g of a medicament with 0.1 g of a commercially available electrolyte material (e.g., one sold under the name ORAL REHYDRATION SALTS, available from Jianas Bros. Packaging Co.). The mixture is then placed onto an electrogel pad, which is "sandwiched" between two ECG patches connected to a voltmeter. Readings in mV are taken over regular intervals (e.g., 5-minute intervals).

When using the medicaments of the invention, a peak (i.e., highest or maximum) metabolic activity of at least about 2.5 mV, preferably at least about 4 mV, and more preferably from about 4-20 mV is achieved. This peak is preferably achieved within about 30 minutes, and more preferably within about 15 minutes, of application to the afflicted area.

The inventive medicaments also possess the property of having a retained metabolic activity of at least about 20%, preferably at least about 30%, and even more preferably from about 50-100% over a 45-minute time period. Furthermore, the inventive medicaments possess the property of having a retained metabolic activity of at least about 5%, preferably at least about 20%, and even more preferably from about 25-100% over an 8-hour time period. As used herein, "retained metabolic activity" is determined as follows :

metabolic activity after 45 minutes or 8 hours

Retained Metabolic Activity = x 100 peak metabolic activity

BRIEF DESCRIPTION OF THE DRAWINGS

Figure Ia is a graph depicting the metabolic activity of a prior art product over a 45-minute time period; Fig. Ib is a graph depicting the metabolic activity of another prior art product over a 45 -minute time period;

Fib. 1 c is a graph depicting the metabolic activity of the inventive medicament over a 45-minute time period; and Fig. 1 d is a graph depicting the metabolic activity of the inventive medicament over an 8-hour time period.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

EXAMPLES

The following examples set forth preferred methods in accordance with the invention. It is to be understood, however, that these examples are provided by way of illustration and nothing therein should be taken as a limitation upon the overall scope of the invention.

EXAMPLE 1

Preparation of Topical Medicament

A 1 -gallon plastic jug was tared on a Sunbeam Model SP5 top balance (no shield, small pan balance). The jug was then charged with 5.7 oz of SOMBRA Natural Pain Relieving Gel (available from Sombra Inc., Albuquerque, NM).

Thirteen potassium amino acid chelate capsules (99 mg potassium with millet filler; available from Nature's Way, Springville, UT) were emptied three at a time. The filled capsule weight was 0.78 g, the emptied powder weight was 0.67 g, and the empty capsule weight was 0.67 g (n=l). The level of elemental potassium in the capsule was not given on the label.

The powder emptied from the capsules was then added to the SOMBRA in the plastic jug as follows:

(1) The jug was charged with SOMBRA to a weight of 12.1 oz., and the powder from three empty capsules was added; (2) The jug was charged with SOMBRA to a weight of 1 Ib. 6.1 oz., and the powder from three empty capsules was added;

(3) The jug was charged with SOMBRA to a weight of 2 Ib. 3.9 oz., and the powder from the remaining empty capsules was added; and (4) The jug was charged to a final weight of 3 Ib. 1 oz. with SOMBRA.

A cap was placed on the jug, and the jug was shaken by hand for about 2 minutes to substantially evenly distribute the powder. The gel did not adhere to the plastic jug after the potassium amino acid chelate was added.

AEROBIC 07 (a dietary supplement including deionized water, sodium chlorite, carbonates, and bicarbonates; available from Aerobic Live, Phoenix, AZ) was used as a stabilized source of oxygen. Thirteen drops of the Aerobic 07 were added to the plastic jug containing the SOMBRA-potassium amino acid chelate mixture. The jug was again capped and shaken by hand for about 2 minutes to yield the final topical medicament. The final medicament was more viscous than the SOMBRA gel. When comparing a quantity of each, the compounded medicament did not separate or flow as compared to the

SOMBRA gel, which showed some physical separation.

EXAMPLE 2 Treatment of Patient A 1. Patient History

The topical medicament prepared in Example 1 was used to treat a patient (hereinafter referred to as "Patient A"). Patient A was a Caucasian female in her 60s, and she was 57" and approximately 220 Ib. Patient A exhibited neuropathy of the legs and feet, with the left leg being worse than the right. Patient A's big toe on her right foot and second toe on her left foot were amputated within the preceding 3 years due to diabetes.

She had received angioplasty about 9 months prior, and the angioplasty improved blood flow to her lower extremities.

Both legs below the knees presented open sores about half-way between the knee caps and ankles. The sores were worse on the right leg than the left. She had used Bactroban and Betadine to treat the topical sores for infection. Patient A also had an ulcer on the bottom of her right foot. She had begun a second, 2-3 week treatment course of Regranex, applying at bedtime. Previous use of Regranex had worked, but the ulcer recurred, so she then had surgery. She began to use Etherex, which she stated is a generic medicine for Regranex and Bactroban. Her daily medications are shown in Table A-B.

Table A

Table B

Patient A also reported using Walitin (generic for Claritin) and Nasonex as needed for allergies.

2. Treatment with Inventive Topical Medicament

The ambient temperature during treatment ranged from 74-78°F according to measurements from four different Stress Thermometers used "as is" (Dr. Lowenstein's Model SC911 accuracy +/- 1.8°F, 10 ft. lead with fast temperature sensor).

Patient A was recumbent on a treatment table with a triangular pillow positioned behind both knees so that the knees were bent upward to rise above the ankles. A temperature probe was strapped on each upper ventral thigh and on the inside of each ankle. The probes were covered, and no medicament was applied to the probes. Equilibration time was approximately 10 minutes after the patient reclined in the prone position. After equilibration time was reached, the temperatures were recorded as shown in Table C.

Table C

The inventive medicament was applied to the top and bottom of each thigh and later (as shown in Table D) to the top and bottom of each calf, ankle, and foot. The product was massaged into the skin until nearly invisible to the eye. The dosage level was 0.3 oz. on each thigh and each ankle for a total per leg dosage of 0.6 oz.

Temperature readings were taken at intervals, beginning 5 minutes after application to Patient A's legs. These readings are set forth in Table D.

Table D

Five minutes after application to left calf and lower thigh (0 time).

Patient A rose from the table at 78 minutes, and the thigh probes were removed. Patient A held the readout portion of the thermometers in her hand while the probes were still attached to the ankles to allow her to walk to the restroom and take a further readout of her ankles after 5 minutes elapsed. However, at 82 minutes the left ankle probe came loose so no reading was taken. The right ankle probe gave a reading of 81.10F at 82 minutes. Patient A reported that her left side (neuropathic side) felt soothed.

EXAMPLE 3 Treatment of Patient B

1. Patient History

The topical medicament prepared in Example 1 was used to treat a second patient

(hereinafter referred to as "Patient B"). Patient B was a 60-year old, 57", Caucasian female. She was a non-insulin dependent diabetic and had sensory neuropathy that was worse in her right leg. She did not have any visible wounds. Her daily oral medications were Glucophage (1 in the evening), Toprol, Diovan, and Lipitor (1 in the evening). 2. Treatment with Inventive Topical Medicament

The ambient temperature during treatment ranged from 74-750F according to measurements from the four different Stress Thermometers as described in Part 2 of Example 2. The probes were applied as described in Part 2 of Example 2. The initial readings are shown in Table E.

Table E

A Temperature prior to medicament application.

B The probe came loose from the right thigh, thus resulting in the 79°F reading. c Temperature at 4 minutes after temperature reading in middle column.

Temperature readings were taken as described in Part 2 of Example 2. These readings and the times of medicament application to Patient B's legs are set forth in Table F.

Table F

A Five minutes after first temperature reading in Table E.

The probes were removed after 70 minutes. EXAMPLE 4

Determination of Metabolic Activity

The topical medicament prepared in Example 1 was applied to the left inner forearm (below the elbow) of a patient. The treated area was then swabbed with a glass slide that was subsequently sandwiched between two ECG patches attached to leads to a Radio Shack digital, multi-meter. The initial reading (time = 0) was 0.0 mV. Subsequent readings were taken at different intervals, and those results are reported in Table G.

Table G

This test was carried out to show that oxygen activation from the compounded medicament occurs following the application to human skin with or without sweat.

This test was repeated using medicament that had been swabbed from another patient's back. However, the cream turned green in color and did not reproduce similar results with the ECG patches. It also took about 6 hours and 20 minutes for this person to notice the heat activation in the location where the medicament had been applied to the back. EXAMPLE 5

Metabolic Activity Comparison

In this test, the metabolic activity of the topical medicament prepared in Example 1 was determined following the steps set forth in Example 4. The same steps were followed to determine the metabolic activity of two prior art products. Fig. Ia shows the metabolic activity of one prior art product (non-modified SOMBRA) over a 45-minute time period. Fig. Ib shows the metabolic activity of another prior art product (non- modified BIO-FREEZE) over a 45-minute time period. Fig. Ic shows the inventive medicament's metabolic activity over a 45-minute time period. A comparison of these figures shows that metabolic activity of the prior art peaks and then drops substantially over the 45-minute time period while the inventive medicament's metabolic activity maintains very high levels even after peaking. Fig. Id shows the inventive medicament's metabolic activity over an 8-hour time period. This graph shows that this activity drops slowly over the 8-hour time period, thus providing prolonged treatment periods as compared to prior art products.

EXAMPLE 6

Treatment of Patient with Inventive Topical Medicament The patient in this example (hereinafter referred to as "Patient C") was a Caucasian female in her late 50s. Patient C was suffering from neuropathy in her feet, with symptoms including sharp, stabbing pains and contractures due to over-stimulation of muscles. The condition had caused Patient C to take disability from work.

The topical medicament prepared in Example 1 was applied to Patient Cs feet.

Within 10 minutes, the contractures in her feet started to release, and she reported that her feet felt 90% better. Also, the sharp, stabbing pain was relieved for 6 hours after treatment.

Claims

I Claim:
1. In a topical medicament comprising menthol and camphor, the improvement being that said medicament further comprises potassium and a source of oxygen.
2. The medicament of claim 1 , wherein said medicament is in the form of a gel.
3. The medicament of claim 1 , wherein said source of oxygen is selected from the group consisting of chlorites, spirulina, and mixtures of the foregoing.
4. The medicament of claim 3, wherein said source of oxygen is an alkali metal chlorite.
5. The medicament of claim 1 , wherein said medicament comprises: at least about 0.5% by weight menthol; at least about 0.5% by weight camphor; at least about 0.02% by weight potassium; and sufficient quantities of said oxygen source to provide at least about 0.016% by weight oxygen, based upon the total weight of the medicament taken as
100% by weight.
6. The medicament of claim 1 , wherein said medicament further comprises an ingredient selected from the group consisting of aloe vera extract, capsaicin, carbomer, decyl plyglucose, deionized water, grapefruit seed extract, green tea extract, orange peel extract, queen of the prairie extract, rose water, silica, sodium hydroxymethyl glycinate, vegetable glycerin, witch hazel, yucca extract, carbonates, bicarbonates, and mixtures of the foregoing.
7. The medicament of claim 1, wherein said medicament has a retained metabolic activity of at least about 20% over a 45-minute time period.
8. The medicament of claim 1, wherein said medicament has a retained metabolic activity of at least about 5% over an 8-hour time period.
9. A method of treating a portion of a body afflicted with an ailment, said method comprising the step of contacting a medicament with the portion of the body afflicted with the ailment, said medicament comprising menthol, camphor, potassium, and a source of oxygen.
10. The method of claim 9, wherein said contacting step comprises rubbing said medicament into the portion of the body afflicted with the ailment.
11. The method of claim 9, wherein said medicament is in the form of a gel.
12. The method of claim 9, wherein said source of oxygen is selected from the group consisting of chlorites, spirulina, and mixtures of the foregoing.
13. The method of claim 12, wherein said source of oxygen is an alkali metal chlorite.
14. The method of claim 9, wherein said medicament comprises: at least about 0.5% by weight menthol; at least about 0.5% by weight camphor; at least about 0.02% by weight potassium; and sufficient quantities of said oxygen source to provide at least about 0.016% by weight oxygen, based upon the total weight of the medicament taken as 100% by weight.
15. The method of claim 9, wherein said medicament further comprises an ingredient selected from the group consisting of aloe vera extract, capsaicin, carbomer, decyl plyglucose, deionized water, grapefruit seed extract, green tea extract, orange peel extract, queen of the prairie extract, rose water, silica, sodium hydroxymethyl glycinate, vegetable glycerin, witch hazel, yucca extract, and mixtures of the foregoing.
16. The method of claim 9, wherein said medicament has a retained metabolic activity of at least about 20% 45 minutes after said contacting step
17. The method of claim 9, wherein said medicament has a retained metabolic activity of at least about 5% 8 hours after said contacting step.
18. A method of preparing a topical medicament, said method comprising the step of mixing together menthol, camphor, potassium, and a source of oxygen.
19. The method of claim 18, wherein said method further comprises the steps of:
(a) providing a precursor composition comprising said menthol and camphor;
(b) adding said potassium to a quantity of said precursor composition to yield a first intermediate composition;
(c) alternately adding further quantities of said precursor composition and said potassium to said first intermediate composition to form a second intermediate composition; and
(d) adding said source of oxygen to said second intermediate composition to yield the topical medicament.
20. The method of claim 19, further comprising the step of mixing said second intermediate composition prior to adding step (d).
PCT/US2005/031819 2004-09-08 2005-09-07 Topical medicament WO2006029189A3 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US60813604 true 2004-09-08 2004-09-08
US60/608,136 2004-09-08
US11/220,138 2005-09-06
US11220138 US7704522B2 (en) 2004-09-08 2005-09-06 Topical medicament

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0704141A GB2432314B (en) 2004-09-08 2005-09-07 Topical medicament comprising menthol, camphor, potassium and a source of oxygen
CA 2579338 CA2579338C (en) 2004-09-08 2005-09-07 A topical medicament comprising menthol,camphor,potassium, and a source of oxygen

Publications (2)

Publication Number Publication Date
WO2006029189A2 true true WO2006029189A2 (en) 2006-03-16
WO2006029189A3 true WO2006029189A3 (en) 2007-05-03

Family

ID=35996542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/031819 WO2006029189A3 (en) 2004-09-08 2005-09-07 Topical medicament

Country Status (4)

Country Link
US (3) US7704522B2 (en)
CA (1) CA2579338C (en)
GB (1) GB2432314B (en)
WO (1) WO2006029189A3 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017004319A1 (en) * 2015-07-01 2017-01-05 Twi Biotechnology, Inc. Diacerein or rhein topical formulations and uses thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704522B2 (en) * 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
US7811554B2 (en) 2007-01-19 2010-10-12 Flavio Lozano Horse liniment
WO2008103345A3 (en) 2007-02-19 2009-09-24 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
US20110189309A1 (en) * 2007-07-12 2011-08-04 Whipbird Pain Relief Pty Ltd Acn 132 827 411 Topical medicament
EP2042167A1 (en) * 2007-09-26 2009-04-01 Aisa Therapeutics Use of a monoterpene to induce tissue repair
US20110021958A1 (en) * 2009-07-27 2011-01-27 Lynds Bruce G Therapeutic Devices And Methods Of Using The Same
CA2796068A1 (en) 2010-04-15 2011-10-20 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly-n-acetylglucosamine nanofibers
CN103648279B (en) * 2011-04-15 2017-05-24 海洋聚合物技术公司 Poly -n- acetylglucosamine treatment of diseases nanofiber
US20130072575A1 (en) * 2011-09-19 2013-03-21 Johnson & Johnson Consumer Companies, Inc. Method and Composition for Treating Pain
US9717757B1 (en) 2011-12-28 2017-08-01 Samuel N. Gasque, Jr. Composition and method to treat and prevent muscle cramping
WO2014193972A1 (en) * 2013-05-29 2014-12-04 Kirkpatrick Melissa Topical examination compositions and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855922A (en) * 1995-12-07 1999-01-05 Bio-Cide International, Inc. Antiseptic composition and process for prophylaxis and therapeutic treatment of dermal disorders
US5955067A (en) * 1996-07-23 1999-09-21 Oge; Eray Potassium-containing composition useful in the treatment of acne, psoriasis and seborrhea
US6328982B1 (en) * 1998-08-04 2001-12-11 Takasago International Corporation Cool feeling composition

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2045618B (en) 1979-04-03 1983-05-11 Hisamitsu Pharmaceutical Co Adhesive plaster
DE3213389A1 (en) 1982-04-10 1983-10-20 Kuehne Friedrich Wilhelm Stabilized activated oxygen and drug containing this stabilized activated oxygen
DE3344691A1 (en) 1983-12-10 1985-06-20 Bayer Ag Drug exhaust systems
DE3347278A1 (en) 1983-12-28 1985-07-11 Bayer Ag Drug delivery systems
DE3347277A1 (en) 1983-12-28 1985-07-11 Bayer Ag Drug delivery systems
DE3409079A1 (en) 1984-03-13 1985-09-19 Bayer Ag medical plaster
US4892890A (en) 1984-11-01 1990-01-09 G. D. Searle And Company External analgesic compositions
LU85643A1 (en) 1984-11-16 1986-06-04 Oreal Cosmetic slimming composition heat-based extracts Plant oil-soluble
JPH0371406B2 (en) 1985-06-24 1991-11-13 Teisan Seiyaku Kk
US4702916A (en) 1985-12-03 1987-10-27 Warner-Lambert Company Analgesic stick compositions
US4963591A (en) 1985-12-16 1990-10-16 Carter-Wallace Inc. Cosmetic compositions
JPH0417931B2 (en) 1986-01-22 1992-03-26 Teisan Seiyaku Kk
US5145675A (en) 1986-03-31 1992-09-08 Advanced Polymer Systems, Inc. Two step method for preparation of controlled release formulations
DE3704907A1 (en) 1987-02-17 1988-08-25 Bayer Ag Topically applicable preparations of gyrase inhibitors in combination with corticosteroid
DE69020900T2 (en) 1989-07-28 1995-12-14 Hisamitsu Pharmaceutical Co Foam aerosol composition.
US5383848A (en) 1990-04-12 1995-01-24 Gensia, Inc. Iontophoretic administration of drugs
US5273754A (en) 1992-03-27 1993-12-28 Mann Morris A Appetite suppressant composition and method relating thereto
US5429590A (en) 1992-12-01 1995-07-04 Nitto Denko Corporation Medical water-absorptive polymer and dressing for wound and medical bandage using the same
US5468492A (en) 1993-07-27 1995-11-21 Biogal Gyogyszergyar Rt Cosmetic composition
DE4341444C2 (en) 1993-12-04 1996-03-14 Lohmann Therapie Syst Lts Active substance-containing plaster, and process for its preparation
US5505958A (en) 1994-10-31 1996-04-09 Algos Pharmaceutical Corporation Transdermal drug delivery device and method for its manufacture
US5597849A (en) 1994-11-14 1997-01-28 Medical Polymer Technologies, Inc. Stick formulations for topical drug delivery of therapeutic agents and uses thereof
US6139850A (en) 1994-12-21 2000-10-31 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5716625A (en) 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5804203A (en) 1994-12-21 1998-09-08 Cosmederm Technologies Topical product formulations containing strontium for reducing skin irritation
ES2179133T3 (en) 1995-03-22 2003-01-16 Dompe Spa Pharmaceutical shaped formations thixotropic gel.
US5866143A (en) 1995-03-24 1999-02-02 El Khoury And Stein, Ltd. Topical application of opioid drugs such as morphine for relief of itching and skin disease
EP0822807B1 (en) 1995-04-26 2000-12-20 Péter KOLTA Gel with increased oxygen content
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5665386A (en) 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
EP0831870A4 (en) 1995-06-07 1998-09-16 Avmax Inc Use of essential oils to increase bioavailability of oral pharmaceutical compounds
EP0750905B1 (en) 1995-06-27 2003-01-02 Kao Corporation Patch comprising water soluble adhesive sheet
US5626856A (en) 1995-06-30 1997-05-06 Safe & Dry Company, Inc. Cosmetic delivery vehicles and related compositions
US5882663A (en) 1995-10-20 1999-03-16 Koeniger; Erich A. Topical pain-relieving preparation containing C12 To C18 isoparaffins
US6239180B1 (en) 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
JP4021516B2 (en) 1996-03-12 2007-12-12 徳山 張 Medicinal plant composition and medicinal plants plasters prepared therefrom
US5716621A (en) 1996-07-03 1998-02-10 Pharmadyn, Inc. Nonocclusive drug delivery device and process for its manufacture
US5830447A (en) 1996-09-04 1998-11-03 The Procter & Gamble Company Personal care compositions
US5916548A (en) 1996-09-04 1999-06-29 The Procter & Gamble Company Personal care compositions
US5804173A (en) 1996-09-04 1998-09-08 The Procter & Gamble Company Personal care compositions
US5863527A (en) 1996-09-04 1999-01-26 The Proctor & Gamble Company Personal care compositions
CA2244256C (en) 1996-11-25 2006-07-11 Toray Industries, Inc. Antipruritic
US6440987B1 (en) 1996-11-25 2002-08-27 Toray Industries, Inc. Antipruritic
US6645506B1 (en) 1997-04-18 2003-11-11 Ganeden Biotech, Inc. Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil
WO1998053825A1 (en) 1997-05-27 1998-12-03 Algos Pharmaceutical Corporation Analgesic drug composition containing a capsaicinoid and potentiator therefor
JP4677063B2 (en) 1997-07-18 2011-04-27 帝國製薬株式会社 Netherlands mustard extract blended external preparations
DE19749467C2 (en) 1997-11-08 1999-09-23 Beiersdorf Ag Plasters containing active substance
US5980925A (en) 1997-12-30 1999-11-09 Ethicon, Inc. High glycerin containing anti-microbial cleansers
US6103266A (en) 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
WO1999062974A1 (en) 1998-06-04 1999-12-09 Kao Corporation Polymer emulsion and process for producing the same
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6258857B1 (en) 1999-02-04 2001-07-10 Kyowa Industrial Co., Ltd. Internal liquid composition contained as internal liquid in a releasing container and releasing container product
US6277401B1 (en) 1999-05-07 2001-08-21 U.S. Dermatologics, Inc. Drug delivery device
US6495498B2 (en) 1999-05-27 2002-12-17 Johnson & Johnson Consumer Companies, Inc. Detergent compositions with enhanced depositing, conditioning and softness capabilities
US6524594B1 (en) 1999-06-23 2003-02-25 Johnson & Johnson Consumer Companies, Inc. Foaming oil gel compositions
US6335023B1 (en) 1999-06-30 2002-01-01 Ruey J. Yu Oligosaccharide aldonic acids and their topical use
JP3724988B2 (en) 1999-07-30 2005-12-07 信越化学工業株式会社 Novel silicone compound and cosmetics containing the same
US6270783B1 (en) 1999-08-13 2001-08-07 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Cosmetic strips with liquid crystal temperature dependent color change
US6306412B1 (en) 1999-08-13 2001-10-23 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Cosmetic strip with an agent for inducing a temperature change
US6653352B2 (en) 1999-09-29 2003-11-25 Medical Merchandising, Inc. Pain reliever and method of use
US6348218B1 (en) 1999-10-04 2002-02-19 Invent Resources, Inc. Self dosing skin preparation
US6582724B2 (en) 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6586000B2 (en) 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6645520B2 (en) 1999-12-16 2003-11-11 Dermatrends, Inc. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
DE10001546A1 (en) 2000-01-14 2001-07-19 Beiersdorf Ag A process for the continuous production and coating of self catering compositions based on polyisobutylene with at least one pharmaceutical active substance
US6635702B1 (en) 2000-04-11 2003-10-21 Noveon Ip Holdings Corp. Stable aqueous surfactant compositions
US6623756B1 (en) 2000-04-27 2003-09-23 Noveon Ip Holdings Corp. Directly compressed solid dosage articles
US6409997B1 (en) 2000-07-31 2002-06-25 Neutrogena Corporation Wax cosmetic stick
US6433061B1 (en) 2000-10-24 2002-08-13 Noveon Ip Holdings Corp. Rheology modifying copolymer composition
WO2002057215A3 (en) 2001-01-16 2002-10-10 Advanced Medicine Inc Sodium channel modulators
EP1355907A1 (en) 2001-01-31 2003-10-29 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
CN1518542A (en) 2001-01-31 2004-08-04 辉瑞产品公司 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
US6589568B2 (en) 2001-02-16 2003-07-08 Nurad, Inc. Therapeutic body lotion containing alkali metal hypohalite
US6592896B2 (en) 2001-08-06 2003-07-15 The Quigley Corporation Medicinal composition and method of using it
US6596313B2 (en) 2001-08-06 2003-07-22 The Quigley Corporation Nutritional supplement and methods of using it
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US6579543B1 (en) 2002-02-22 2003-06-17 Jackie H. McClung Composition for topical application to skin
US7704522B2 (en) 2004-09-08 2010-04-27 Clyde Morgan Topical medicament

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855922A (en) * 1995-12-07 1999-01-05 Bio-Cide International, Inc. Antiseptic composition and process for prophylaxis and therapeutic treatment of dermal disorders
US5955067A (en) * 1996-07-23 1999-09-21 Oge; Eray Potassium-containing composition useful in the treatment of acne, psoriasis and seborrhea
US6328982B1 (en) * 1998-08-04 2001-12-11 Takasago International Corporation Cool feeling composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017004319A1 (en) * 2015-07-01 2017-01-05 Twi Biotechnology, Inc. Diacerein or rhein topical formulations and uses thereof

Also Published As

Publication number Publication date Type
GB0704141D0 (en) 2007-04-11 grant
US8541034B2 (en) 2013-09-24 grant
CA2579338C (en) 2014-07-08 grant
WO2006029189A3 (en) 2007-05-03 application
US7704522B2 (en) 2010-04-27 grant
GB2432314A (en) 2007-05-23 application
US20080069903A1 (en) 2008-03-20 application
GB2432314B (en) 2009-10-28 grant
US8048447B2 (en) 2011-11-01 grant
US20060051432A1 (en) 2006-03-09 application
US20090017138A1 (en) 2009-01-15 application
CA2579338A1 (en) 2006-03-16 application

Similar Documents

Publication Publication Date Title
US20080311167A1 (en) Topical Composition for Treating Pain
WO2008112561A1 (en) Combination therapy for alleviating pain-related conditions
Kučera et al. Efficacy and safety of topically applied Symphytum herb extract cream in the treatment of ankle distortion: Results of a randomized controlled clinical double-blind study
CN1255361A (en) Multifunctional health-care wine
Kucera et al. TopicalSymphytum herb concentrate cream against myalgia: A randomized controlled double-blind clinical study
US6203796B1 (en) Oregano-based therapeutic composition
WO2006032091A2 (en) Herbal composition
Ho et al. A new approach to patch testing patients with para‐phenylenediamine allergy secondary to temporary black henna tattoos
WO2001005416A1 (en) Oil from momordica charantia l., its method of preparation and uses
CN101971894A (en) Compound burdock health protection tea
CN201157562Y (en) Warm-application muscles and bones rheumatism emplastrum
Timme A new pluriglandular compensatory syndrome
JP2002322071A (en) Vespid venom therapy not using vespid sting
US20060216338A1 (en) Composition and method of treatment for heel pain
Le Coz Allergic contact dermatitis from tamanu oil (Calophyllum inophyllum, Calophyllum tacamahaca)
US5972340A (en) Slimming cream based on plants
Kleyn et al. Contact dermatitis from 3 different allergens in Solaraze® gel
Spiewak Köbnerizing occupational contact allergy to thiuram in a farmer with psoriasis
CN1176134A (en) Active aloe glue
CN103055091A (en) Bone cure pain eliminating paste
Matsumura et al. Widespread contact dermatitis from tocopherol acetate
US20100331415A1 (en) Use of omega-3-fatty acid(s)
CN101773642A (en) Gukangling plaster formula for activating blood and dissolving stasis and preparation method
CN1270833A (en) Bone fracture setting medicine powder
CN102274321A (en) Chinese medicine for treating tendon injury composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2579338

Country of ref document: CA

ENP Entry into the national phase in:

Ref document number: 0704141

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20050907

WWE Wipo information: entry into national phase

Ref document number: 0704141.1

Country of ref document: GB

WWE Wipo information: entry into national phase

Ref document number: 2005282502

Country of ref document: AU

NENP Non-entry into the national phase in:

Ref country code: DE

ENP Entry into the national phase in:

Ref document number: 2005282502

Country of ref document: AU

Date of ref document: 20050907

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005282502

Country of ref document: AU

122 Ep: pct application non-entry in european phase